Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

14.95
+0.12000.81%
Post-market: 15.000.0500+0.33%19:30 EDT
Volume:281.25K
Turnover:4.19M
Market Cap:38.69M
PE:- -
High:15.17
Open:15.07
Low:14.73
Close:14.83
52wk High:36.00
52wk Low:9.23
Shares:2.59M
Float Shares:2.59M
Volume Ratio:0.66
T/O Rate:10.87%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Benzinga Earnings
·
Aug 05

NYSE Most Active Issues

Dow Jones
·
Aug 05

The Wegovy Pill's 'surprise Miss' is One Reason Novo Nordisk's Stock is Down

Dow Jones
·
Aug 05

Wegovy Maker Novo Nordisk Lifts Annual Forecast Amid Rising Demand for Weight-Loss Drugs

Deep News
·
Aug 05

Novo Nordisk Raises Earnings Guidance. the Stock Sinks.

Dow Jones
·
Aug 05

Wegovy-Maker Novo Nordisk Raises Full-Year Guidance as Appetite for Weight-Loss Drugs Grows

Dow Jones
·
Aug 05

Novo Nordisk Lifts 2026 Outlook After Strong Q2 Adjusted Results

TIPRANKS
·
Aug 05

Novo Nordisk Q2 Lifts FY Guidance on Stronger GLP-1 Demand

Reuters
·
Aug 05

Novo Nordisk Boosts Adjusted Sales, Operating Profit Guidance for 2026

MT Newswires Live
·
Aug 05

Novo Nordisk reports Q2 adjusted sales DKK 78.49B, up 7% at CER

TIPRANKS
·
Aug 05

Novo Nordisk raises FY26 adjusted sales view to 0% to down 6% from down 4%-12%

TIPRANKS
·
Aug 05

Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users

TIPRANKS
·
Aug 05

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

TIPRANKS
·
Aug 04

Legal Inquiry Launched for Hims & Hers Health Following Share Plunge

Deep News
·
Aug 04

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 04

Novo Nordisk Earnings Seen Lower; Guidance and Wegovy Pill in Focus

Dow Jones
·
Aug 03

Stock Markets Can't Rely on Tech to Power Gains Anymore

Dow Jones
·
Aug 03

Novo Nordisk A/S Expected to Post Earnings of Dkk4.99 a Share - Earnings Preview

Reuters
·
Aug 03

Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Simply Wall St.
·
Aug 02

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

TIPRANKS
·
Aug 01